LUCY Innovative Eyewear Inc
Ophthalmic Goods · Nasdaq · SEC CIK 1808377 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY56.9%
TTM net income YoY-3.7%
TTM EPS YoY42.4%
Revenue 3-yr CAGR83.9%
Net income 3-yr CAGR—
Margins
Gross margin22.7%
Operating margin—
Net margin-216.8%
FCF margin—
EBITDA margin—
Returns
ROE-92.4%
ROA-84.0%
ROIC (approx.)—
Asset turnover0.39x
Leverage & solvency
Liabilities / assets10.2%
Debt / equity0.00x
Current ratio9.12x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-9.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.66M | $1.64M | $1.15M | $659,788 | $690,670 |
| Cost of revenue | $2.09M | $1.42M | $1.27M | $716,077 | $542,416 |
| Gross profit | $567,451 | $215,190 | -$119,329 | -$56,289 | $148,254 |
| R&D expense | $725,388 | $819,387 | $662,184 | $524,692 | $86,261 |
| SG&A expense | $5.23M | $4.47M | $3.89M | $2.80M | $1.39M |
| Interest expense | — | — | $3,036 | $105,171 | $39,433 |
| Net income | -$7.59M | -$7.77M | -$6.66M | -$5.68M | -$3.24M |
| EPS (basic) | -1.90 | -5.19 | -10.87 | -0.87 | — |
| EPS (diluted) | -1.90 | -5.19 | -10.87 | -0.87 | — |
| Weighted avg. shares (diluted) | 3.99M | 1.50M | 613,000 | 6.53M | — |
| Balance sheet | |||||
| Cash & equivalents | $6.51M | $2.63M | $4.29M | $3.59M | $79,727 |
| Receivables | $142,152 | $107,918 | $93,211 | $110,258 | $43,394 |
| Inventory | $1.75M | $831,757 | $533,239 | $94,701 | $275,501 |
| Current assets | $9.44M | $9.24M | $5.62M | $4.24M | $644,327 |
| PP&E, net | $61,777 | $107,562 | $154,848 | $119,744 | $20,284 |
| Intangibles | $559,968 | $451,302 | $286,429 | $137,557 | $87,306 |
| Total assets | $10.14M | $9.84M | $6.22M | $4.69M | $824,317 |
| Current liabilities | $1.05M | $737,718 | $624,486 | $600,005 | $616,801 |
| Total liabilities | $1.07M | $743,168 | $659,936 | $665,455 | $616,801 |
| Shareholders' equity | $9.07M | $9.10M | $5.56M | $4.02M | $207,516 |
| Shares outstanding | 5.48M | 2.45M | 747,416 | 7.31M | 6.06M |
| Cash flow statement | |||||
| Operating cash flow | -$7.28M | -$6.74M | -$5.77M | -$3.22M | -$1.21M |
| Capital expenditure | $72,513 | $62,203 | $78,463 | $121,561 | $20,782 |
| Free cash flow | -$7.35M | -$6.80M | -$5.84M | -$3.35M | -$1.23M |
| Investing cash flow | $4.48M | -$5.16M | -$198,753 | -$219,951 | -$118,454 |
| Financing cash flow | $6.68M | $10.24M | $6.66M | $6.96M | $1.39M |
| Depreciation & amortization | $66,788 | $109,489 | $61,093 | $22,101 | $498 |
| Stock-based compensation | $738,170 | $774,788 | $936,769 | $1.47M | $1.33M |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.